Date: 2015-07-14
Type of information: Nomination
Compound:
Company: MDxHealth (Belgium)
Therapeutic area: Cancer - Oncology - Diagnostic
Type agreement: nomination
Action mechanism:
Disease:
Details: * On July 14, 2015, MDxHealth announced the appointment of Philip J. Ginsburg, MD, as Chief Medical Officer (CMO). Dr. Ginsburg joins the company with over 20 years of commercial medical laboratory and urology experience. In this new role, Dr. Ginsburg will have overall responsibility for clinical strategy, including scientific and clinical affairs. Before joining MDxHealth, Dr. Ginsburg was CMO, at Toma Biosciences, Iris International, Inc. and President of Arista, a personalized medicine division of Iris acquired by Beckman Coulter a subsidiary of Danaher Corporation. Prior to Iris International, Dr. Ginsburg was Chief Executive Officer, co-founder and CMO of AlliedPath, a CLIA molecular diagnostic laboratory focussing on urology, which was ultimately acquired by Iris International in July 2010. Dr. Ginsburg also served as Senior Medical Director at Gen-Probe, Inc., where he was involved with the clinical development program for their PCA3 test for prostate cancer detection and formerly served as a medical director at Quest Diagnostics. Dr. Ginsburg earned his medical degree at the University of Pretoria School of Medicine, South Africa, later specializing in clinical pathology at the University of Witwatersrand and the South African Institute of Medical Research.
Financial terms:
Latest news:
